June 25 (Reuters) - AbbVie said on Tuesday the U.S. Food and Drug Administration has rejected the company's marketing application for its therapy to treat motor fluctuations in adults with advanced Parkinson's disease. (Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)